# PDUFA dates October 2026: FDA calendar and catalysts

Canonical: https://sec-api.dev/fda-calendar/2026-10

> 188 FDA catalysts are dated in October 2026, including 9 PDUFA dates.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What PDUFA dates are in October 2026?

PDUFA dates in October 2026: MK-7902 (MRK) on October 4, 2026; Merck & Co., Inc. (MRK) on October 10, 2026; MR-141 (VTRS) on October 17, 2026; Opus Genetics, Inc. (IRD) on October 17, 2026; Joenja® (leniolisib, PHAR) on October 24, 2026; Pharming Group N.V. (PHAR) on October 24, 2026; and 3 more. [Calendar and source filings](https://sec-api.dev/fda-calendar/2026-10)

Source: SEC Form 10-Q, accession 0000310158-26-000212, https://www.sec.gov/Archives/edgar/data/310158/000031015826000212/mrk-20260630.htm (retrieved 2026-11-12). Last confirmed 2026-08-07. Cite: https://sec-api.dev/fda-calendar/2026-10#answer

## PDUFA dates in October 2026

Data as of November 16, 2026.

| PDUFA date | Company | Ticker | Drug | Indication | Source |
| --- | --- | --- | --- | --- | --- |
| October 4, 2026 | Merck & Co., Inc. | MRK | MK-7902 |  | [SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/310158/000031015826000212/mrk-20260630.htm) |
| October 10, 2026 | Merck & Co., Inc. | MRK |  |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/310158/000110465926052081/tm2612241d1_ex99-1.htm) |
| October 17, 2026 | Viatris Inc | VTRS | MR-141 | presbyopia | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1792044/000179204426000010/exhibit991-4q25earningsrel.htm) |
| October 17, 2026 | Opus Genetics, Inc. | IRD |  | presbyopia - | [SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1228627/000162828026054381/ird-20260630.htm) |
| October 24, 2026 | Pharming Group N.V. | PHAR | Joenja® (leniolisib) |  | [SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831626000033/a2026hy1pressrelease.htm) |
| October 24, 2026 | Pharming Group N.V. | PHAR |  |  | [SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831626000031/pharmingannouncesusfdaacce.htm) |
| October 26, 2026 | GSK plc | GSK | HIBSAGO (bepirovirsen) |  | [SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1131399/000165495426004051/a2755c.htm) |
| October 26, 2026 | IONIS PHARMACEUTICALS INC | IONS |  |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/874015/000114036126029960/ef20078953_ex99-1.htm) |
| October 30, 2026 | INOVIO PHARMACEUTICALS, INC. | INO | INO-3107 |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1055726/000105572626000024/ino-63026x8kex991.htm) |

## All catalysts in October 2026

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| October 1, 2026 | [ARAKODA® (tafenoquine) interim data readout](https://sec-api.dev/pdufa/tafenoquine) | SXTP |  | scheduled | "Enrollment required for the prespecified interim analysis is complete, and the Data Safety Monitoring Board ("DSMB") analysis is scheduled for October 1, 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1946563/000121390026099702/ea0305442-8k_60degree.htm)) |
| October 1, 2026 | [TRUTAKNA (atacicept) topline data readout](https://sec-api.dev/pdufa/atacicept) | VERA | IgA Nephropathy; Berger Disease | completed | "NCT04716231 (Atacicept in Subjects With IgA Nephropathy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-05-15 (ACTUAL); Lead Sponsor Vera Therapeutics, Inc.; Results First Posted 2026-10-01." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04716231?tab=results)) |
| October 1, 2026 | [1h incubation photodynamic therapy (pdt) (ala-pdt, ameluz®-pdt) topline data readout](https://sec-api.dev/pdufa/1h-incubation-photodynamic-therapy-pdt-ala-pdt-ameluz-pdt) | BFRI | Acne Vulgaris | completed | "NCT05080764 (Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-08-22 (ACTUAL); Lead Sponsor Biofrontera Inc.; Results First Posted 2026-10-01." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05080764?tab=results)) |
| October 1, 2026 | [Foundayo (orforglipron calcium) topline data readout](https://sec-api.dev/pdufa/orforglipron) | LLY | Type 2 Diabetes | completed | "NCT06109311 (A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-15 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-10-01." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06109311?tab=results)) |
| October 2026 | [Ziltivekimab primary completion](https://sec-api.dev/pdufa/ziltivekimab) | NVO | Heart Failure; Systemic Inflammation | delayed | "NCT06200207 (A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-01 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06200207)) |
| October 1, 2026 | [JAKAFI (ruxolitinib) primary completion](https://sec-api.dev/pdufa/ruxolitinib) | INCY | Chronic Graft-versus-host-disease | completed | "NCT06388564 (A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10-01 (ACTUAL); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06388564)) |
| October 1, 2026 | [Ruxolitinib cream primary completion](https://sec-api.dev/pdufa/ruxolitinib-cream) | INCY | Hidradenitis Suppurativa | completed | "NCT06958211 (Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-01 (ACTUAL); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06958211)) |
| October 2, 2026 | [BGE-102 trial start](https://sec-api.dev/pdufa/bge-102) | BIOA | diabetic macular edema | completed | "BioAge Labs, Inc. (the "Company") recently announced that the first participant has been dosed in QUELL-DME, a randomized, controlled Phase 2 trial evaluating once-daily oral BGE-102, an NLRP3 inhibitor, in adults with diabetic macular edema ("DME"), and provided updates on the QUELL-DME Phase 2 trial design." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1709941/000119312526412300/bioa-20261002.htm)) |
| October 2, 2026 | [Tev-53408 dose a primary completion](https://sec-api.dev/pdufa/tev-53408) | TEVA | Celiac Disease | completed | "NCT06807463 (A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10-02 (ACTUAL); Lead Sponsor Teva Branded Pharmaceutical Products R&D LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06807463)) |
| October 2, 2026 | [Jaypirca (pirtobrutinib) label expansion decision](https://sec-api.dev/pdufa/pirtobrutinib) | LLY |  | completed, approved | "NDA216059 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20261002, review_priority STANDARD; sponsor_name LOXO ONCOL; product JAYPIRCA (PIRTOBRUTINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA216059%22)) |
| October 4, 2026 | [MK-7902 PDUFA date](https://sec-api.dev/pdufa/mk-7902) | MRK |  | scheduled | "In the U.S., the FDA set a PDUFA date of October 4, 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/310158/000031015826000212/mrk-20260630.htm)) |
| October 4, 2026 | [Topical ocular bl1332 low dose primary completion](https://sec-api.dev/pdufa/topical-ocular-bl1332) | BLCO | Pain, Postoperative | completed | "NCT07412496 (A Study to Evaluate the Use of Topical Ocular BL1332 for the Management of Postoperative Ocular Pain Following Photorefractive Keratectomy): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-10-04 (ACTUAL); Lead Sponsor Bausch & Lomb Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07412496)) |
| October 5, 2026 | [AMJEVITA® (adalimumab) FDA approval](https://sec-api.dev/pdufa/adalimumab) | ALVO |  | completed, approved | "REYKJAVIK, Iceland, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has approved a supplement to the Biologics License Application (BLA) for AVT02 (adalimumab-ryvk), marketed in the U.S. as SIMLANDI®, enabling drug substance for the product to be manufactured in a second production suite at the company's Reykjavik facility." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1898416/000117184326006383/exh_991.htm)) |
| October 5, 2026 | [VAX-31 topline data readout](https://sec-api.dev/pdufa/vax-31) | PCVX |  | completed, positive | "SAN CARLOS, Calif., October 5, 2026 - Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced positive topline results from the OPUS-1 pivotal adult Phase 3 trial evaluating the safety, tolerability and immunogenicity of VAX-31, the Company's next-generation 31-valent pneumococcal conjugate vaccine (PCV) candidate, for the prevention of invasive pneumococcal disease (IPD) and pneumococcal pneumonia." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649094/000119312526413168/d21202dex991.htm)) |
| October 5, 2026 | [TEPKINLY (epcoritamab) topline data readout](https://sec-api.dev/pdufa/epcoritamab) | GMAB |  | completed, positive | "Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) announced today positive topline results from the Phase 3 EPCORE DLBCL-2 trial evaluating fixed treatment duration epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in combination with standard of care rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (R-CHOP), compared to R-CHOP alone, in newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of 2 to 5." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1434265/000143426526000132/gmab_20261015xex99d1.htm)) |
| October 2026 | [Karxt primary completion](https://sec-api.dev/pdufa/karxt) | BMY | Psychosis Associated With Alzheimer's Disease | delayed | "NCT05511363 (A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-10-05 (ESTIMATED); Lead Sponsor Karuna Therapeutics, Inc., a Bristol Myers Squibb company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05511363)) |
| October 6, 2026 | [Carotuximab interim data readout](https://sec-api.dev/pdufa/carotuximab) | KAPA | metastatic castration-resistant prostate cancer | completed, positive | "ANGELES — October 6, 2026 — Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company addressing drug resistance in cancer, today announced positive interim efficacy data from its ongoing Phase 2 clinical trial evaluating ENV-105 (carotuximab) in combination with apalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1962011/000149315226045844/ex99-1.htm)) |
| October 6, 2026 | [TRUSELTIQ® (infigratinib) NDA/BLA acceptance](https://sec-api.dev/pdufa/infigratinib) | BBIO | children with achondroplasia | completed | "PALO ALTO, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, today announced the FDA has accepted for filing its New Drug Application (NDA) with Priority Review for oral infigratinib for the treatment of children with achondroplasia." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1743881/000114036126039334/ef20083591_ex99-1.htm)) |
| October 6, 2026 | [TAK-101 topline data readout](https://sec-api.dev/pdufa/tak-101) | TAK | Celiac Disease | completed | "NCT04530123 (Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-12-09 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-10-06." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04530123?tab=results)) |
| October 6, 2026 | [Furmonertinib primary completion](https://sec-api.dev/pdufa/furmonertinib) | AVBP |  | completed | "NCT05607550 (Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-06 (ACTUAL); Lead Sponsor ArriVent BioPharma, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05607550)) |
| October 2026 | [Admilparant primary completion](https://sec-api.dev/pdufa/admilparant) | BMY | Idiopathic Pulmonary Fibrosis | delayed | "NCT06003426 (A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-06 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06003426)) |
| October 6, 2026 | [Salbutamol hfa-134a topline data readout](https://sec-api.dev/pdufa/salbutamol-hfa-134a) | GSK | Asthma | completed | "NCT06261957 (A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-02 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-10-06." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06261957?tab=results)) |
| October 6, 2026 | [Rhapsido® (remibrutinib) label expansion decision](https://sec-api.dev/pdufa/remibrutinib) | NVS |  | completed, approved | "NDA218436 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20261006, review_priority STANDARD; sponsor_name NOVARTIS; product RHAPSIDO (REMIBRUTINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218436%22)) |
| October 7, 2026 | [Verastem, Inc. NDA/BLA acceptance](https://sec-api.dev/companies/vstm/catalysts) | VSTM |  | completed | "On October 7, 2026, the FDA accepted for review our Blister Pack New Drug Application (the "NDA") for the first quarter of 2027 and notified us that the NDA has been granted priority review." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1526119/000110465926115875/tm2627537-1_424b5.htm)) |
| October 7, 2026 | [Itepekimab (sar440340) topline data readout](https://sec-api.dev/pdufa/itepekimab-sar440340) | SNY | Bronchiectasis | completed | "NCT06280391 (A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-09-16 (ACTUAL); Lead Sponsor Sanofi; Results First Posted 2026-10-07." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06280391?tab=results)) |
| October 7, 2026 | [Menacyw conjugate vaccine topline data readout](https://sec-api.dev/pdufa/menacyw-conjugate-vaccine) | SNY | Meningococcal Immunisation; Healthy Volunteers | completed | "NCT06284915 (Study on Immunogenicity and Safety of a Meningococcal ACYW Conjugate Vaccine in Healthy Infants and Toddlers): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-14 (ACTUAL); Lead Sponsor Sanofi Pasteur, a Sanofi Company; Results First Posted 2026-10-07." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06284915?tab=results)) |
| October 7, 2026 | [Tukysa (tucatinib) label expansion decision](https://sec-api.dev/pdufa/tucatinib) | PFE |  | completed, approved | "NDA213411 SUPPL-10 (Efficacy): submission_status AP, submission_status_date 20261007, review_priority STANDARD; sponsor_name SEAGEN; product TUKYSA (TUCATINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213411%22)) |
| October 8, 2026 | [FB102 topline data readout](https://sec-api.dev/pdufa/fb102) | ARGX | celiac disease | completed, positive | "Amsterdam, the Netherlands - argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced positive topline results from the Phase 2 study evaluating FB102, a first-in-class CD122 inhibitor, in adults with celiac disease." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1697862/000110465926114491/tm2627263d1_ex99-1.htm)) |
| October 8, 2026 | [Breztri Aerosphere (budesonide; formoterol fumarate; glycopyrrolate) FDA approval](https://sec-api.dev/pdufa/budesonide-formoterol-glycopyrrolate) | AZN |  | completed, approved | "NDA220290 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20261008, review_priority STANDARD; sponsor_name ASTRAZENECA AB; product BREZTRI AEROSPHERE (BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA220290%22)) |
| October 8, 2026 | [MRNA-1083 topline data readout](https://sec-api.dev/pdufa/mrna-1083) | MRNA | Influenza; SARS-CoV-2 | completed | "NCT06508320 (A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-09-25 (ACTUAL); Lead Sponsor ModernaTX, Inc.; Results First Posted 2026-10-08." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06508320?tab=results)) |
| October 8, 2026 | [WELTRUZATM (olanzapine) FDA approval](https://sec-api.dev/pdufa/olanzapine) | TEVA | schizophrenia in adults | completed, approved | "NDA219007 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20261008, review_priority STANDARD; sponsor_name TEVA; product WELTRUZA (OLANZAPINE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA219007%22)) |
| October 9, 2026 | [OLUMIANT® (baricitinib) label expansion decision](https://sec-api.dev/pdufa/baricitinib) | LLY |  | completed, approved | "NDA207924 SUPPL-10 (Efficacy): submission_status AP, submission_status_date 20261009, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product OLUMIANT (BARICITINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA207924%22)) |
| October 9, 2026 | [Repatha (evolocumab) label expansion decision](https://sec-api.dev/pdufa/evolocumab) | AMGN |  | completed, approved | "BLA125522 SUPPL-47 (Efficacy): submission_status AP, submission_status_date 20261009, review_priority STANDARD; sponsor_name AMGEN INC; product REPATHA (EVOLOCUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125522%22)) |
| October 9, 2026 | [Dupixent (dupilumab) primary completion](https://sec-api.dev/pdufa/dupilumab) | REGN | Atopic Dermatitis | completed | "NCT02612454 (Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-10-09 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02612454)) |
| October 9, 2026 | [AFX3772 topline data readout](https://sec-api.dev/pdufa/afx3772) | GSK | Pneumonia, Bacterial; Pneumococcal Infections; Pneumonia, Pneumococcal | completed | "NCT05412030 (A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-09-18 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-10-09." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05412030?tab=results)) |
| October 9, 2026 | [PF-07868489 primary completion](https://sec-api.dev/pdufa/pf-07868489) | PFE | Pulmonary Hypertension | withdrawn | "NCT07073820 (A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-10-09 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07073820)) |
| October 10, 2026 | [Merck & Co., Inc. PDUFA date](https://sec-api.dev/companies/mrk/catalysts) | MRK |  | scheduled | "§ FDA set Prescription Drug User Fee Act (PDUFA) date of Oct. 10, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/310158/000110465926052081/tm2612241d1_ex99-1.htm)) |
| October 12, 2026 | [ARR-002 trial start](https://sec-api.dev/pdufa/arr-002) | AVBP |  | completed | "ArriVent Announces First Patient Dosed with" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1868279/000110465926115161/tm2627450d1_ex99-1.htm)) |
| October 12, 2026 | [Nurix Therapeutics, Inc. earnings report](https://sec-api.dev/companies/nrix/catalysts) | NRIX |  | completed | "Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1549595/000154959526000048/nrix-20261013xexx991.htm)) |
| October 12, 2026 | [ANB033 topline data readout](https://sec-api.dev/pdufa/anb033) | TRAX |  | completed, positive | "SAN DIEGO, CA — Oct. 12, 2026 — First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today announced positive top-line results from Cohort 1 (gluten challenge) of ANB033's Phase 1b trial in celiac disease (CeD)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2091349/000119312526419761/trax-ex99_2.htm)) |
| October 2026 | [Erleada (apalutamide) primary completion](https://sec-api.dev/pdufa/apalutamide) | JNJ | Metastatic Castrate-sensitive Prostate Cancer | delayed | "NCT05884398 (A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-12 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05884398)) |
| October 13, 2026 | [Ontunisertib trial start](https://sec-api.dev/pdufa/ontunisertib) | AGMB | symptomatic FSCD | completed | "- Agomab Therapeutics NV ('Agomab'), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced that the first patient has been dosed in NOV-ERA, the Company's global Phase 2b study evaluating ontunisertib in patients with symptomatic FSCD." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2020932/000110465926115567/tm2627540d1_ex99-1.htm)) |
| October 14, 2026 | [ENTR-601 topline data readout](https://sec-api.dev/pdufa/entr-601) | TRDA |  | completed, positive | "On October 14, 2026, the Company announced positive topline data from Cohort 1 of the double-blind, placebo-controlled, multiple ascending dose (MAD) portion of the Phase 1/2 ELEVATE-45-201 clinical study of ENTR-601-45 in ambulatory participants with a confirmed mutation in the DMD gene amenable to exon 45 skipping." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1689375/000168937526000057/trda-20261014.htm)) |
| October 14, 2026 | [ANKTIVA (inbakicept) label expansion decision](https://sec-api.dev/pdufa/inbakicept) | IBRX | BGC-unresponsive nonmuscle invasive bladder cancer | completed, approved | "•FDA Expanded Approval: On October 14, 2026, the U.S. Food and Drug Administration (FDA) approved our supplemental Biologics License Application (sBLA) expanding the approved indication for ANKTIVA® in combination with Bacillus Calmette-Guérin (BCG) to include adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1326110/000132611026000097/ibrx-2026119x8kexhibit991.htm)) |
| October 14, 2026 | [MAXCYTE, INC. earnings report](https://sec-api.dev/companies/mxct/catalysts) | MXCT |  | completed | "MaxCyte will report royalty revenue with its full financial results on November 10, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1287098/000110465926115745/tm2627568d1_ex99-1.htm)) |
| October 14, 2026 | [Joenja® (leniolisib) topline data readout](https://sec-api.dev/pdufa/leniolisib) | PHAR |  | completed, positive | "On October 14, 2026, we presented positive topline data from our Phase II trial of leniolisib in genetically identifiable PIDs with immune dysregulation at the 22nd Biennial Meeting of the European Society for Immunodeficiencies (ESID)." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831626000049/a2026q3pressrelease.htm)) |
| October 14, 2026 | [Enflonsia (clesrovimab-cfor) label expansion decision](https://sec-api.dev/pdufa/clesrovimab-cfor) | MRK |  | completed, approved | "BLA761432 SUPPL-3 (Efficacy): submission_status AP, submission_status_date 20261014, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product ENFLONSIA (CLESROVIMAB-CFOR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761432%22)) |
| October 14, 2026 | [Tapinarof cream, 1% primary completion](https://sec-api.dev/pdufa/tapinarof-cream-1) | OGN | Plaque Psoriasis | completed | "NCT05172726 (Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-10-14 (ACTUAL); Lead Sponsor Organon and Co." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05172726)) |
| October 15, 2026 | [Inhaled treprostinil topline data readout](https://sec-api.dev/pdufa/inhaled-treprostinil) | UTHR | Idiopathic Pulmonary Fibrosis; Interstitial Lung Disease | completed | "NCT05255991 (Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-30 (ACTUAL); Lead Sponsor United Therapeutics; Results First Posted 2026-10-15." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05255991?tab=results)) |
| October 2026 | [Milvexian primary completion](https://sec-api.dev/pdufa/milvexian) | JNJ | Ischemic Stroke; Ischemic Attack, Transient | delayed | "NCT05702034 (A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-15 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05702034)) |
| October 15, 2026 | [Elx/tez/iva topline data readout](https://sec-api.dev/pdufa/elx-tez-iva) | VRTX | Cystic Fibrosis | completed | "NCT05882357 (Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-04 (ACTUAL); Lead Sponsor Vertex Pharmaceuticals Incorporated; Results First Posted 2026-10-15." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05882357?tab=results)) |
| October 15, 2026 | [Pelacarsen primary completion](https://sec-api.dev/pdufa/pelacarsen) | NVS | Hyperlipoproteinemia (a) | withdrawn | "NCT05900141 (An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2026-10-15 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05900141)) |
| October 15, 2026 | [Carbetocin topline data readout](https://sec-api.dev/pdufa/carbetocin) | ACAD | Hyperphagia in Prader-Willi Syndrome | completed | "NCT06173531 (Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-19 (ACTUAL); Lead Sponsor ACADIA Pharmaceuticals Inc.; Results First Posted 2026-10-15." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06173531?tab=results)) |
| October 15, 2026 | [Cosentyx (secukinumab) label expansion decision](https://sec-api.dev/pdufa/secukinumab) | NVS |  | completed, approved | "BLA761349 SUPPL-13 (Efficacy): submission_status AP, submission_status_date 20261015, review_priority STANDARD; sponsor_name NOVARTIS PHARMS CORP; product COSENTYX (SECUKINUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761349%22)) |
| October 16, 2026 | [Opus Genetics, Inc. label expansion decision](https://sec-api.dev/companies/ird/catalysts) | IRD | presbyopia in adults | completed, approved | "On October 16, 2026, the FDA approved the Company's supplemental New Drug Application (sNDA) for phentolamine ophthalmic solution 0.75% for the treatment of presbyopia in adults." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1228627/000162828026072697/ird-20260930.htm)) |
| October 16, 2026 | [Brytly (apraclonidine hydrochloride) FDA approval](https://sec-api.dev/pdufa/apraclonidine) | ALC |  | completed, approved | "NDA220341 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20261016, review_priority STANDARD; sponsor_name ALCON LABS INC; product BRYTLY (APRACLONIDINE HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA220341%22)) |
| October 16, 2026 | [Keytruda Qlex (berahyaluronidase alfa-pmph; pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/berahyaluronidase-alfa-pmph-pembrolizumab) | MRK |  | completed, approved | "BLA761467 SUPPL-8 (Efficacy): submission_status AP, submission_status_date 20261016, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA QLEX (BERAHYALURONIDASE ALFA-PMPH; PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761467%22)) |
| October 16, 2026 | [Foundayo (orforglipron calcium) topline data readout](https://sec-api.dev/pdufa/orforglipron) | LLY | Type 2 Diabetes | completed | "NCT06192108 (A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-26 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-10-16." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06192108?tab=results)) |
| October 16, 2026 | [Lebrikizumab topline data readout](https://sec-api.dev/pdufa/lebrikizumab) | LLY | Atopic Dermatitis | completed | "NCT06280716 (A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-25 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-10-16." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06280716?tab=results)) |
| October 16, 2026 | [KEYTRUDA® (pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed, approved | "BLA125514 SUPPL-191 (Efficacy): submission_status AP, submission_status_date 20261016, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22)) |
| October 17, 2026 | [MR-141 PDUFA date](https://sec-api.dev/pdufa/mr-141) | VTRS | presbyopia | scheduled | "the FDA has assigned a PDUFA goal date of October 17, 2026 for MR-141 (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1792044/000179204426000010/exhibit991-4q25earningsrel.htm)) |
| October 17, 2026 | [Opus Genetics, Inc. PDUFA date](https://sec-api.dev/companies/ird/catalysts) | IRD | presbyopia - | scheduled | "In February 2026, the FDA accepted the sNDA and set a Prescription Drug User Fee Act (PDUFA) action date of October 17, 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1228627/000162828026054381/ird-20260630.htm)) |
| October 19, 2026 | [Jemperli (dostarlimab) FDA approval](https://sec-api.dev/pdufa/dostarlimab) | GSK | stage II and III microsatellite instability-high | completed, approved | "GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab) as the first and only immunotherapy for adults with stage II and III microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) locally advanced rectal cancer under the accelerated approval pathway." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1131399/000165495426009036/a5712z.htm)) |
| October 19, 2026 | [Veradermics, Inc topline data readout](https://sec-api.dev/companies/mane/catalysts) | MANE |  | completed, positive | "On October 19, 2026, the Company announced positive topline data from the Phase 3 clinical trial, Study '304' evaluating VDPHL01 in males with mild-to-moderate pattern hair loss." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1827635/000182763526000036/mane-20261019.htm)) |
| October 19, 2026 | [CNM-Au8 (cnm-au8) NDA/BLA submission](https://sec-api.dev/pdufa/cnm-au8) | CLNN | amyotrophic lateral sclerosis | completed | "SALT LAKE CITY, October 19, 2026 — Clene Inc. (Nasdaq: CLNN), a clinical-stage biotechnology company focused on revolutionizing the treatment of neurodegenerative diseases, announced that it has submitted a New Drug Application (NDA) earlier in October to the U.S. Food and Drug Administration (FDA) seeking accelerated approval of CNM-Au8® for the treatment of amyotrophic lateral sclerosis (ALS)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1822791/000143774926032882/ex_1027473.htm)) |
| October 19, 2026 | [Bitopertin topline data readout](https://sec-api.dev/pdufa/bitopertin) | IRON |  | completed, positive | "On October 19, 2026, the Company announced positive topline results from the APOLLO Phase 3 trial of bitopertin in EPP, including X-linked protoporphyria ("XLP")." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1816736/000119312526424649/d156263d8k.htm)) |
| October 19, 2026 | [REZZAYO® (rezafungin) NDA/BLA acceptance](https://sec-api.dev/pdufa/rezafungin) | CRMD |  | completed | "NJ - October 19, 2026 - CorMedix Therapeutics (Nasdaq: CRMD) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Application (sNDA) seeking approval of REZZAYO® (rezafungin for injection)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1410098/000121390026110477/ea030895701ex99-1.htm)) |
| October 19, 2026 | [Jemperli (dostarlimab-gxly) label expansion decision](https://sec-api.dev/pdufa/dostarlimab-gxly) | GSK |  | completed, approved | "BLA761174 SUPPL-15 (Efficacy): submission_status AP, submission_status_date 20261019, review_priority PRIORITY; sponsor_name GLAXOSMITHKLINE; product JEMPERLI (DOSTARLIMAB-GXLY)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761174%22)) |
| October 2026 | [Sotyktu (deucravacitinib) primary completion](https://sec-api.dev/pdufa/deucravacitinib) | BMY | Systemic Lupus Erythematosus | delayed | "NCT05617677 (A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-19 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05617677)) |
| October 2026 | [Sotyktu (deucravacitinib) primary completion](https://sec-api.dev/pdufa/deucravacitinib) | BMY | Systemic Lupus Erythematosus | delayed | "NCT05620407 (A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-19 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05620407)) |
| October 19, 2026 | [Sacituzumab tirumotecan primary completion](https://sec-api.dev/pdufa/sacituzumab-tirumotecan) | MRK | Gastroesophageal Cancer | completed | "NCT06356311 (A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-19 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06356311)) |
| October 2026 | [Povofortay (povorcitinib) primary completion](https://sec-api.dev/pdufa/povorcitinib) | INCY | Prurigo Nodularis | delayed | "NCT06516952 (A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-19 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06516952)) |
| October 20, 2026 | [RAP-219 topline data readout](https://sec-api.dev/pdufa/rap-219) | RAPP |  | completed, positive | "On October 20, 2026, the Company announced positive topline results from its Phase 2 trial of RAP-219 for the treatment of bipolar mania." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/2012593/000119312526425647/d185134d8k.htm)) |
| October 20, 2026 | [AMJEVITA® (adalimumab) FDA approval](https://sec-api.dev/pdufa/adalimumab) | ALVO |  | completed, approved | "REYKJAVIK, Iceland and LONDON, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has approved a new manufacturing process for SIMLANDI® (adalimumab-ryvk), Alvotech's biosimilar to Humira® (adalimumab)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1898416/000117184326006704/exh_991.htm)) |
| October 20, 2026 | [HIBSAGO (bepirovirsen) FDA approval](https://sec-api.dev/pdufa/bepirovirsen) | GSK | chronic hepatitis B | completed, approved | "Hibsago \| bepirovirsen \| 10/20/2026 \| To treat chronic hepatitis B virus infection in certain adults without cirrhosis, in combination with existing antiviral therapy" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)) |
| October 20, 2026 | [Medpace Holdings, Inc. earnings report](https://sec-api.dev/companies/medp/catalysts) | MEDP |  | completed | "Medpace Holdings, Inc. Reports Third Quarter 2026 Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1668397/000166839726000034/medp-20261021exx991.htm)) |
| October 20, 2026 | [Ustekinumab dose based on bsa and body weight topline data readout](https://sec-api.dev/pdufa/ustekinumab-dose-based-on-bsa-and-body-weight) | JNJ | Colitis, Ulcerative | completed | "NCT04630028 (A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-08 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC; Results First Posted 2026-10-20." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04630028?tab=results)) |
| October 2026 | [Litifilimab primary completion](https://sec-api.dev/pdufa/litifilimab) | BIIB | Subacute Cutaneous Lupus Erythematosus; Chronic Cutaneous Lupus Erythematosus | delayed | "NCT05531565 (A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-10-20 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05531565)) |
| October 21, 2026 | [ABBOTT LABORATORIES earnings report](https://sec-api.dev/companies/abt/catalysts) | ABT |  | completed | "Abbott Reports Third-Quarter 2026 Results and Reaffirms Full-Year EPS Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1800/000162828026066601/abt-2026q3xexhibitx991.htm)) |
| October 21, 2026 | [ORLADEYO® (berotralstat) label expansion decision](https://sec-api.dev/pdufa/berotralstat) | BCRX |  | completed, approved | "On October 21, 2026, we announced that the FDA approved the supplemental new drug application for use of the 150 mg oral pellet formulation of once-daily ORLADEYO for prophylactic therapy in adults and adolescents aged 12 years and older." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/882796/000162828026070112/bcrx-20260930.htm)) |
| October 21, 2026 | [Brentuximab vedotin topline data readout](https://sec-api.dev/pdufa/brentuximab-vedotin) | PFE | Diffuse Large B-cell Lymphoma | completed | "NCT04404283 (Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-01-23 (ACTUAL); Lead Sponsor Seagen, a wholly owned subsidiary of Pfizer; Results First Posted 2026-10-21." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04404283?tab=results)) |
| October 21, 2026 | [Venclexta (venetoclax) topline data readout](https://sec-api.dev/pdufa/venetoclax) | ABBV | Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL) | completed | "NCT05105841 (Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-10-09 (ACTUAL); Lead Sponsor AbbVie; Results First Posted 2026-10-21." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05105841?tab=results)) |
| October 21, 2026 | [Yeztugo® (lenacapavir) topline data readout](https://sec-api.dev/pdufa/lenacapavir) | GILD | HIV-1-infection | completed | "NCT05502341 (Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2025-09-29 (ACTUAL); Lead Sponsor Gilead Sciences; Results First Posted 2026-10-21." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05502341?tab=results)) |
| October 21, 2026 | [ORKA-001 primary completion](https://sec-api.dev/pdufa/orka-001) | ORKA | Plaque Psoriasis | completed | "NCT07290569 (Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10-21 (ACTUAL); Lead Sponsor Oruka Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07290569)) |
| October 21, 2026 | [31-valent pneumococcal conjugate vaccine primary completion](https://sec-api.dev/pdufa/31-valent-pneumococcal-conjugate-vaccine) | PCVX | Pneumococcal Disease | completed | "NCT07365826 (A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-10-21 (ACTUAL); Lead Sponsor Vaxcyte, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07365826)) |
| October 21, 2026 | [Ultomiris (ravulizumab-cwvz) label expansion decision](https://sec-api.dev/pdufa/ravulizumab-cwvz) | AZN |  | completed, approved | "BLA761108 SUPPL-46 (Efficacy): submission_status AP, submission_status_date 20261021, review_priority PRIORITY; sponsor_name ALEXION PHARM; product ULTOMIRIS (RAVULIZUMAB-CWVZ)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761108%22)) |
| October 22, 2026 | [VYGLXIA (troriluzole) NDA/BLA acceptance](https://sec-api.dev/pdufa/troriluzole) | BHVN | spinocerebellar ataxia | completed | "On October 22, 2026, we announced that the FDA has accepted for review our new drug application ("NDA") resubmission for Vyglxia (troriluzole) for the treatment of spinocerebellar ataxia ("SCA")." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1935979/000193597926000092/bhvn-20260930.htm)) |
| October 22, 2026 | [Pavblu (aflibercept-ayyh) FDA approval](https://sec-api.dev/pdufa/aflibercept-ayyh) | AMGN |  | completed, approved | "BLA761298 ORIG-2: submission_status AP, submission_status_date 20261022, review_priority STANDARD; sponsor_name AMGEN INC; product PAVBLU (AFLIBERCEPT-AYYH)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761298%22)) |
| October 22, 2026 | [KEYTRUDA® (pembrolizumab) topline data readout](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Triple Negative Breast Neoplasms | completed | "NCT03036488 (Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-10-14 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-10-22." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03036488?tab=results)) |
| October 22, 2026 | [REC-994 topline data readout](https://sec-api.dev/pdufa/rec-994) | RXRX | Cerebral Cavernous Malformation | completed | "NCT05085561 (The Symptomatic Cerebral Cavernous Malformation Trial of REC-994): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-30 (ACTUAL); Lead Sponsor Recursion Pharmaceuticals Inc.; Results First Posted 2026-10-22." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05085561?tab=results)) |
| October 2026 | [Dazodalibep primary completion](https://sec-api.dev/pdufa/dazodalibep) | AMGN | Sjögren's Syndrome (SS) | delayed | "NCT06245408 (A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-22 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06245408)) |
| October 22, 2026 | [LY3650150 primary completion](https://sec-api.dev/pdufa/ly3650150) | LLY | Perennial Allergic Rhinitis (PAR) | completed | "NCT06339008 (A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-22 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06339008)) |
| October 23, 2026 | [Rinatabart topline data readout](https://sec-api.dev/pdufa/rinatabart) | GMAB | platinum-resistant ovarian cancer | completed, positive | "Genmab A/S (Nasdaq: GMAB) announced today positive topline results from the global Phase 3 RAINFOL™-02 trial of rinatabart sesutecan (Rina-S®), an investigational folate receptor alpha (FRα)-targeted, topoisomerase I (TOPO1)-inhibitor antibody-drug conjugate (ADC), in patients with platinum-resistant ovarian cancer (PROC) regardless of FRα expression level or prior treatment with mirvetuximab." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1434265/000143426526000138/gmab_20261023xex99d1.htm)) |
| October 23, 2026 | [MGC026 interim data readout](https://sec-api.dev/pdufa/mgc026) | MGNX |  | completed, positive | "ROCKVILLE, Md., October 23, 2026 -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced positive interim data from its Phase 1 study evaluating MGC026, a B7-H3-directed antibody-drug conjugate (ADC), in patients with advanced solid tumors." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1125345/000112534526000066/a991pressreleasedatedoctob.htm)) |
| October 23, 2026 | [Awiqli Flextouch (insulin icodec) label expansion decision](https://sec-api.dev/pdufa/insulin-icodec) | NVO |  | completed, approved | "BLA761326 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20261023, review_priority PRIORITY; sponsor_name NOVO NORDISK INC; product AWIQLI FLEXTOUCH (INSULIN ICODEC)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761326%22)) |
| October 2026 | [AZD6234 primary completion](https://sec-api.dev/pdufa/azd6234) | AZN | Obesity/Overweight | delayed | "NCT07017179 (This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10-23 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07017179)) |
| October 23, 2026 | [Skyrizi (risankizumab-rzaa) label expansion decision](https://sec-api.dev/pdufa/risankizumab-rzaa) | ABBV |  | completed, approved | "BLA761105 SUPPL-53 (Efficacy): submission_status AP, submission_status_date 20261023, review_priority PRIORITY; sponsor_name ABBVIE INC; product SKYRIZI (RISANKIZUMAB-RZAA)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761105%22)) |
| October 24, 2026 | [Joenja® (leniolisib) PDUFA date](https://sec-api.dev/pdufa/leniolisib) | PHAR |  | completed, approved | "The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of October 24, 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831626000033/a2026hy1pressrelease.htm)) |
| October 24, 2026 | [Pharming Group N.V. PDUFA date](https://sec-api.dev/companies/phar/catalysts) | PHAR |  | scheduled | "The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of October 24, 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831626000031/pharmingannouncesusfdaacce.htm)) |
| October 25, 2026 | [PCV20 primary completion](https://sec-api.dev/pdufa/pcv20) | PCVX | Pneumococcal Disease | completed | "NCT07425392 (Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-10-25 (ACTUAL); Lead Sponsor Vaxcyte, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07425392)) |
| October 26, 2026 | [HIBSAGO (bepirovirsen) PDUFA date](https://sec-api.dev/pdufa/bepirovirsen) | GSK |  | completed, approved | "In Q1, the US FDA accepted for priority review a New Drug Application (NDA) for bepirovirsen and set 26 October 2026 as the decision goal date." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1131399/000165495426004051/a2755c.htm)) |
| October 26, 2026 | [EQ504 trial start](https://sec-api.dev/pdufa/eq504) | EQ |  | completed | "On October 26, 2026, concurrent with the first patient dosed in the Phase 1 clinical trial, Equillium closed the second tranche of the Company's previously announced August 2025 equity private placement agreement, resulting in aggregate gross proceeds of approximately $20 million." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1746466/000119312526458379/eq-ex99_1.htm)) |
| October 26, 2026 | [Acumen Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/abos/catalysts) | ABOS |  | completed | "Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1576885/000162828026067129/abos-20261026xexx991.htm)) |
| October 26, 2026 | [Jemperli (dostarlimab) interim data readout](https://sec-api.dev/pdufa/dostarlimab) | GSK | stage II and III microsatellite instability-high | completed, positive | "GSK plc (LSE/NYSE: GSK) today announced positive interim results from the phase II AZUR-1 trial evaluating Jemperli (dostarlimab) monotherapy as a standalone treatment approach in adults with stage II and III microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) locally advanced rectal cancer." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1131399/000165495426009130/a3301a.htm)) |
| October 26, 2026 | [IONIS PHARMACEUTICALS INC PDUFA date](https://sec-api.dev/companies/ions/catalysts) | IONS |  | scheduled | "Granted Priority Review in the U.S. and PDUFA target action date of October 26, 2026 o" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/874015/000114036126029960/ef20078953_ex99-1.htm)) |
| October 2026 | [Leqvio (inclisiran sodium) primary completion](https://sec-api.dev/pdufa/inclisiran) | NVS | Coronary Artery Disease | delayed | "NCT05360446 (Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-26 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05360446)) |
| October 26, 2026 | [Jemperli (dostarlimab) primary completion](https://sec-api.dev/pdufa/dostarlimab) | GSK | Lung Cancer, Non-Small Cell | completed | "NCT05565378 (A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10-26 (ACTUAL); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05565378)) |
| October 26, 2026 | [Retatrutide primary completion](https://sec-api.dev/pdufa/retatrutide) | LLY | Type 2 Diabetes | completed | "NCT06297603 (Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-26 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06297603)) |
| October 26, 2026 | [Altsonflex1-2-3 dose a topline data readout](https://sec-api.dev/pdufa/altsonflex1-2-3) | GSK | Diarrhoea | completed | "NCT06663436 (A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-10-21 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-10-26." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06663436?tab=results)) |
| October 26, 2026 | [Fp/abs primary completion](https://sec-api.dev/pdufa/fp-abs) | TEVA | Asthma | completed | "NCT06664619 (A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-10-26 (ACTUAL); Lead Sponsor Teva Branded Pharmaceutical Products R&D LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06664619)) |
| October 26, 2026 | [Talzenna (talazoparib tosylate) label expansion decision](https://sec-api.dev/pdufa/talazoparib) | PFE |  | completed, approved | "NDA217439 SUPPL-4 (Efficacy): submission_status AP, submission_status_date 20261026, review_priority PRIORITY; sponsor_name PFIZER; product TALZENNA (TALAZOPARIB TOSYLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217439%22)) |
| October 27, 2026 | [REPLIGEN CORP earnings report](https://sec-api.dev/companies/rgen/catalysts) | RGEN |  | completed | "Repligen Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/730272/000162828026067405/rgen-20261027xexx991.htm)) |
| October 27, 2026 | [Atrium Therapeutics, Inc. trial start](https://sec-api.dev/companies/rna/catalysts) | RNA | Protein Kinase AMP-activated non-catalytic subunit Gamma 2 | completed | "On October 27, 2026, Atrium Therapeutics, Inc. (the "Company") issued a press release announcing that the first patient has been dosed in the Company's Phase 1/2 Corventis clinical trial evaluating ATR 1072, its lead investigational therapy for the potential treatment of Protein Kinase AMP-activated non-catalytic subunit Gamma 2 ("PRKAG2") syndrome." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/2093101/000119312526432949/d134020d8k.htm)) |
| October 27, 2026 | [Wave Life Sciences, Inc. earnings report](https://sec-api.dev/companies/wve/catalysts) | WVE |  | completed | "Wave Life Sciences Reports Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1631574/000119312526432690/d120442dex991.htm)) |
| October 27, 2026 | [PALI-2108 trial start](https://sec-api.dev/pdufa/pali-2108) | PALI |  | completed | "Dosed the first patient in ASCENTRA-UC on October 27, 2026, marking an important milestone in the clinical development of PALI-2108 for ulcerative colitis ("UC")." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1357459/000135745926000025/pali-ex99_1.htm)) |
| October 27, 2026 | [Kiniksa Pharmaceuticals International, plc earnings report](https://sec-api.dev/companies/knsa/catalysts) | KNSA |  | completed | "Kiniksa Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Portfolio Execution" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1730430/000173043026000037/knsa-ex99d1.htm)) |
| October 27, 2026 | [Zura Bio Ltd earnings report](https://sec-api.dev/companies/zura/catalysts) | ZURA |  | completed | "Zura Bio Reports Third Quarter 2026 Financial Results and Recent Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1855644/000185564426000012/zura-20261027xex991.htm)) |
| October 27, 2026 | [IQVIA HOLDINGS INC. earnings report](https://sec-api.dev/companies/iqv/catalysts) | IQV |  | completed | "IQVIA Reports Third-Quarter 2026 Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1478242/000162828026067406/iqv-q3x2026earningspressre.htm)) |
| October 27, 2026 | [NRC HEALTH earnings report](https://sec-api.dev/companies/nrc/catalysts) | NRC |  | completed | "NRC HEALTH ANNOUNCES THIRD QUARTER 2026 RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/70487/000143774926033639/ex_1031593.htm)) |
| October 27, 2026 | [Taf primary completion](https://sec-api.dev/pdufa/taf) | GILD | Chronic Hepatitis B | completed | "NCT02932150 (Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10-27 (ACTUAL); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02932150)) |
| October 27, 2026 | [AZD3427 topline data readout](https://sec-api.dev/pdufa/azd3427) | AZN | Pulmonary Hypertension (World Health Organization Group 2); Heart Failure | completed | "NCT05737940 (A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-15 (ACTUAL); Lead Sponsor AstraZeneca; Results First Posted 2026-10-27." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05737940?tab=results)) |
| October 2026 | [Volrustomig primary completion](https://sec-api.dev/pdufa/volrustomig) | AZN | Hepatocellular Carcinoma; Biliary Tract Cancer | delayed | "NCT05775159 (Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10-27 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05775159)) |
| October 2026 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Carcinoma, Non-Small-Cell Lung | delayed | "NCT06008093 (A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10-27 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06008093)) |
| October 27, 2026 | [GSK4532990 topline data readout](https://sec-api.dev/pdufa/gsk4532990) | GSK | Non-alcoholic Fatty Liver Disease | completed | "NCT06104319 (Dose Exploration Study of GSK4532990 in. Participants With NASH or Suspected NASH): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-09-23 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-10-27." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06104319?tab=results)) |
| October 28, 2026 | [AMARIN CORP PLCUK earnings report](https://sec-api.dev/companies/amrn/catalysts) | AMRN |  | completed | "Amarin Reports 2026 Third Quarter Financial Results, Achieves Positive Net Income" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/897448/000119312526435081/amrn-ex99_1.htm)) |
| October 28, 2026 | [Rapamycin NDA/BLA acceptance](https://sec-api.dev/pdufa/rapamycin) | PVLA | microcystic lymphatic malformations | completed | "On October 28, 2026, Palvella Therapeutics, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration ("FDA") has accepted for filing and granted Priority Review to the Company's New Drug Application for QTORIN 3.9% rapamycin anhydrous gel for the treatment of microcystic lymphatic malformations." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1583648/000119312526435113/pvla-20261028.htm)) |
| October 28, 2026 | [Cyclo™ (remibetadex) NDA/BLA submission](https://sec-api.dev/pdufa/remibetadex) | RFL |  | completed | "Our primary focus is to obtain FDA approval of Trappsol® Cyclo™, for which we submitted a New Drug Application on October 28, 2026 following the recent completion of Cyclo's pivotal Phase 3 clinical trial, and, if approved, to bring that product to market." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1713863/000121390026113659/ea0309115-10k_rafael.htm)) |
| October 28, 2026 | [DBV Technologies S.A. earnings report](https://sec-api.dev/companies/dbvt/catalysts) | DBVT |  | completed | "DBV Technologies Reports Third Quarter 2026 Financial Results and Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1613780/000119312526436411/d137106dex991.htm)) |
| October 28, 2026 | [LENZ Therapeutics, Inc. earnings report](https://sec-api.dev/companies/lenz/catalysts) | LENZ |  | completed | "LENZ Therapeutics Reports Third Quarter 2026 Financial Results, Announces Strategic Consumer Marketing Focused Reorganization and CEO Succession" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1815776/000181577626000056/a991q326pressrelease.htm)) |
| October 28, 2026 | [Viking Therapeutics, Inc. earnings report](https://sec-api.dev/companies/vktx/catalysts) | VKTX |  | completed | "Viking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1607678/000119312526436145/vktx-ex99_1.htm)) |
| October 28, 2026 | [Replimune Group, Inc. earnings report](https://sec-api.dev/companies/repl/catalysts) | REPL |  | completed | "2026 - Replimune Group, Inc. (Nasdaq: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal second quarter ended September 30, 2026 and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1737953/000110465926119354/tm2628395d1_ex99-1.htm)) |
| October 28, 2026 | [BIOGEN INC. earnings report](https://sec-api.dev/companies/biib/catalysts) | BIIB |  | completed | "Biogen Reports Third Quarter 2026 Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/875045/000087504526000094/exhibit991-q32026pressrele.htm)) |
| October 28, 2026 | [Petosemtamab topline data readout](https://sec-api.dev/pdufa/petosemtamab) | GMAB |  | completed, positive | "Genmab A/S (Nasdaq: GMAB) today announced positive topline results from the global Phase 3 LiGeR-HN1 trial (NCT06525220) evaluating petosemtamab, an investigational IgG1-bispecific antibody targeting the epidermal growth factor receptor (EGFR) and the leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5), in combination with pembrolizumab versus pembrolizumab in patients with first-line (1L) PD-L1 positive recurrent/metastatic head and neck squamous cell carcinoma (HNSCC)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1434265/000143426526000140/gmab_20261028xex99d1.htm)) |
| October 28, 2026 | [Bausch Health Companies Inc. earnings report](https://sec-api.dev/companies/bhc/catalysts) | BHC |  | completed | "BAUSCH HEALTH ANNOUNCES THIRD QUARTER 2026 RESULTS, RAISES GUIDANCE" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/885590/000088559026000121/ex991-q32026.htm)) |
| October 28, 2026 | [Vanda Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/vnda/catalysts) | VNDA |  | completed | "Vanda Pharmaceuticals Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1347178/000162828026067886/vnda8-k10282026exhibit991.htm)) |
| October 28, 2026 | [Dbv712 250 mcg topline data readout](https://sec-api.dev/pdufa/dbv712) | DBVT | Peanut Allergy | completed | "NCT03859700 (Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-13 (ACTUAL); Lead Sponsor DBV Technologies; Results First Posted 2026-10-28." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03859700?tab=results)) |
| October 2026 | [WELIREG® (belzutifan) primary completion](https://sec-api.dev/pdufa/belzutifan) | MRK | Carcinoma, Renal Cell | delayed | "NCT05239728 (A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-28 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05239728)) |
| October 28, 2026 | [AZD2693 topline data readout](https://sec-api.dev/pdufa/azd2693) | AZN | Nonalcoholic Steatohepatitis | completed | "NCT05809934 (A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-14 (ACTUAL); Lead Sponsor AstraZeneca; Results First Posted 2026-10-28." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05809934?tab=results)) |
| October 29, 2026 | [Stoke Therapeutics, Inc. earnings report](https://sec-api.dev/companies/stok/catalysts) | STOK |  | completed | "Stoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1623526/000119312526437775/stok-ex99_1.htm)) |
| October 29, 2026 | [ALNYLAM PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/alny/catalysts) | ALNY |  | completed | "Alnylam Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Period Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1178670/000117867026000074/alny2026q3earningsrelease.htm)) |
| October 29, 2026 | [Immuneering Corp earnings report](https://sec-api.dev/companies/imrx/catalysts) | IMRX |  | completed | "Immuneering Reports Third Quarter 2026 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1790340/000179034026000095/imrx-20261029xexx991.htm)) |
| October 29, 2026 | [ELI LILLY & Co earnings report](https://sec-api.dev/companies/lly/catalysts) | LLY |  | completed | "Lilly reports third-quarter 2026 financial results, raises full-year guidance and highlights regulatory progress across the portfolio" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/59478/000005947826000104/q326lillysalesandearningsp.htm)) |
| October 29, 2026 | [Biohaven Ltd. earnings report](https://sec-api.dev/companies/bhvn/catalysts) | BHVN |  | completed | "Biohaven Reports Recent Business Developments and Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1935979/000193597926000093/a2026q3bhvnearningsprex991.htm)) |
| October 29, 2026 | [EXELIXIS, INC. earnings report](https://sec-api.dev/companies/exel/catalysts) | EXEL |  | completed | "Exelixis Announces Third Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/939767/000093976726000114/exel20260930exhibit991.htm)) |
| October 29, 2026 | [Mineralys Therapeutics, Inc. earnings report](https://sec-api.dev/companies/mlys/catalysts) | MLYS |  | completed | "Mineralys Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000142/mlys2026q38kex991.htm)) |
| October 29, 2026 | [Attruby (acoramidis) earnings report](https://sec-api.dev/pdufa/acoramidis) | BBIO |  | completed | "PALO ALTO, Calif., October 29, 2026 -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today its financial results for the third quarter ended September 30, 2026, and provided an update on Attruby's commercial progress." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1743881/000174388126000033/bbio-20260930xex991.htm)) |
| October 29, 2026 | [PTC THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/ptct/catalysts) | PTCT |  | completed | "PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1070081/000110465926120200/tmb-ex99d1.htm)) |
| October 29, 2026 | [Phathom Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/phat/catalysts) | PHAT |  | completed | "Phathom Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1783183/000119312526436959/d180192dex991.htm)) |
| October 29, 2026 | [LIGAND PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/lgnd/catalysts) | LGND |  | completed | "Ligand Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/886163/000088616326000058/q32026earningsrelease_ex991.htm)) |
| October 29, 2026 | [INSMED Inc earnings report](https://sec-api.dev/companies/insm/catalysts) | INSM |  | completed | "Insmed Reports Third-Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1104506/000114036126041097/ef20084500_ex99-1.htm)) |
| October 29, 2026 | [KT-579 earnings report](https://sec-api.dev/pdufa/kt-579) | KYMR |  | completed | "Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1815442/000119312526436965/kymr-ex99_1.htm)) |
| October 29, 2026 | [TACTI-004 trial start](https://sec-api.dev/pdufa/tacti-004) | IMMP |  | completed | "As previously announced, a proposed investigator-initiated Phase II trial evaluating neoadjuvant efti as monotherapy and in combination with chemotherapy prior to surgery in early-stage HR+/HER2-negative breast cancer remains on hold pending completion of the root cause analysis related to TACTI-004 and further strategic decisions." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1506184/000119312526442214/d183841dex991.htm)) |
| October 29, 2026 | [Merck & Co., Inc. earnings report](https://sec-api.dev/companies/mrk/catalysts) | MRK |  | completed | "USA Announces Third-Quarter 2026 Financial Results; Highlights Multiple Milestones Advancing Broad, Diverse Pipeline" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/310158/000110465926119825/tm2628203d1_ex99-1.htm)) |
| October 29, 2026 | [INCYTE CORP earnings report](https://sec-api.dev/companies/incy/catalysts) | INCY |  | completed | "Incyte Reports Third Quarter 2026 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/879169/000087916926000063/incy-q32026xexx991.htm)) |
| October 29, 2026 | [Rafael Holdings, Inc. earnings report](https://sec-api.dev/companies/rfl/catalysts) | RFL |  | completed | "Inc. (NYSE: RFL) today reported its financial results for the fourth quarter and full fiscal year 2026 ended July 31, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1713863/000121390026113564/ea030996101ex99-1.htm)) |
| October 29, 2026 | [BICYCLE THERAPEUTICS PLC earnings report](https://sec-api.dev/companies/bcyc/catalysts) | BCYC |  | completed | "- Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the third quarter ended September" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1761612/000110465926119858/tm2628394d1_ex99-1.htm)) |
| October 29, 2026 | [Supernus, Inc. earnings report](https://sec-api.dev/companies/supn/catalysts) | SUPN |  | completed | "Indivior Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1625297/000119312526436953/d169609dex991.htm)) |
| October 29, 2026 | [Trappsol (trappsol) NDA/BLA submission](https://sec-api.dev/pdufa/trappsol) | RFL |  | completed | "On October 29, 2026, the Company distributed over a wire service and posted the attached press release (the "Release") to the investors page of its website announcing Cyclo Therapeutics, LLC, has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of remibetadex (Trappsol®" ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1713863/000121390026113564/ea0309961-8k_rafael.htm)) |
| October 29, 2026 | [GILEAD SCIENCES, INC. earnings report](https://sec-api.dev/companies/gild/catalysts) | GILD |  | completed | "GILEAD SCIENCES ANNOUNCES THIRD QUARTER 2026 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882095/000088209526000037/exhibit991earningspressrel.htm)) |
| October 29, 2026 | [BRISTOL MYERS SQUIBB CO earnings report](https://sec-api.dev/companies/bmy/catalysts) | BMY |  | completed | "Bristol Myers Squibb Reports Third Quarter Financial Results for 2026 and Raises Full-Year Revenue Outlook" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/14272/000001427226000022/a2026q3ex991-filing.htm)) |
| October 29, 2026 | [KEYTRUDA® (pembrolizumab) topline data readout](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Carcinoma, Non-Small-Cell Lung | completed | "NCT04165083 (KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-10-31 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-10-29." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04165083?tab=results)) |
| October 29, 2026 | [Ianalumab primary completion](https://sec-api.dev/pdufa/ianalumab) | NVS | Primary Immune Thrombocytopenia (ITP) | completed | "NCT05653349 (Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-29 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05653349)) |
| October 29, 2026 | [Sabirnetug primary completion](https://sec-api.dev/pdufa/sabirnetug) | ABOS | Alzheimer Disease | completed | "NCT06335173 (A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10-29 (ACTUAL); Lead Sponsor Acumen Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06335173)) |
| October 29, 2026 | [Ruxolitinib cream primary completion](https://sec-api.dev/pdufa/ruxolitinib-cream) | INCY | Hidradenitis Suppurativa | completed | "NCT06959225 (Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-29 (ACTUAL); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06959225)) |
| October 30, 2026 | [Skyrizi® (risankizumab) FDA approval](https://sec-api.dev/pdufa/risankizumab) | ABBV | moderately to severely active Crohn's disease | completed, approved | "•AbbVie announced the U.S. Food and Drug Administration (FDA) approved Skyrizi (risankizumab) for subcutaneous (SC) induction in the treatment of moderately to severely active Crohn's disease (CD)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1551152/000155115226000033/abbv-20260930xexhibit991.htm)) |
| October 30, 2026 | [Ultragenyx Pharmaceutical Inc. earnings report](https://sec-api.dev/companies/rare/catalysts) | RARE |  | completed | "Ultragenyx Reports Third Quarter 2026 Financial Results, Announces Substantial Expense Reductions, and Reaffirms Profitability in 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1515673/000119312526445342/rare-ex99_1.htm)) |
| October 30, 2026 | [REGENERON PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/regn/catalysts) | REGN |  | completed | "Tarrytown, New York (October 30, 2026) -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced financial results for the third quarter of 2026 and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000087258926000032/exhibit991q32026.htm)) |
| October 30, 2026 | [OmniAb, Inc. earnings report](https://sec-api.dev/companies/oabi/catalysts) | OABI |  | completed | "OmniAb Reports Third Quarter 2026 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1846253/000184625326000049/a2026q3ex991.htm)) |
| October 30, 2026 | [INOVIO PHARMACEUTICALS, INC. FDA approval](https://sec-api.dev/companies/ino/catalysts) | INO |  | completed, approved | "INOVIO Announces FDA Accelerated Approval of" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1055726/000119312526442648/d150457dex991.htm)) |
| October 30, 2026 | [Aurinia Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/auph/catalysts) | AUPH |  | completed | "Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1600620/000160062026000074/exhibit991_q32026earningsr.htm)) |
| October 30, 2026 | [INO-3107 NDA/BLA acceptance](https://sec-api.dev/pdufa/ino-3107) | INO |  | completed | " the FDA's acceptance of our BLA for INO-3107 with a PDUFA target action date set for October 30, 2026, and the yet-to-be scheduled meeting with the FDA to discuss eligibility for the accelerated approval program;" ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1055726/000119312526451932/d141720d424b5.htm)) |
| October 30, 2026 | [INO-3107 PDUFA date](https://sec-api.dev/pdufa/ino-3107) | INO |  | scheduled | "The FDA's review of the BLA for INO-3107 continues to advance under the Agency's accelerated approval program toward a PDUFA target action date of October 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1055726/000105572626000024/ino-63026x8kex991.htm)) |
| October 30, 2026 | [AbbVie Inc. earnings report](https://sec-api.dev/companies/abbv/catalysts) | ABBV |  | completed | "AbbVie Reports Third-Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1551152/000155115226000033/abbv-20260930xexhibit991.htm)) |
| October 30, 2026 | [KETAFREE (ketamine) FDA approval](https://sec-api.dev/pdufa/ketamine) | NRXP |  | completed, approved | "The Company will host a conference call at 8:30 a.m. ET on Friday, October 30, 2026, to discuss the FDA approval of Preservative-Free Ketamine." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1719406/000143774926034284/ex_1035048.htm)) |
| October 30, 2026 | [Juvmo (tavapadon) FDA approval](https://sec-api.dev/pdufa/tavapadon) | ABBV | with Parkinson's disease | completed, approved | "•AbbVie announced the FDA approved Juvmo (tavapadon) tablets as the only selective D1/D5 receptor agonist for the treatment of adults with Parkinson's disease (PD)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1551152/000155115226000033/abbv-20260930xexhibit991.htm)) |
| October 2026 | [Cerezyme (imiglucerase) primary completion](https://sec-api.dev/pdufa/imiglucerase) | SNY | Gaucher Disease Type 1; Gaucher Disease Type 3 | delayed | "NCT02843035 (Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10-30 (ESTIMATED); Lead Sponsor Genzyme, a Sanofi Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02843035)) |
| October 2026 | [Encorafenib primary completion](https://sec-api.dev/pdufa/encorafenib) | PFE | Melanoma | delayed | "NCT04657991 (A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-30 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04657991)) |
| October 2026 | [Vx-121/tez/d-iva primary completion](https://sec-api.dev/pdufa/vx-121-tez-d-iva) | VRTX | Cystic Fibrosis | delayed | "NCT05444257 (A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-30 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05444257)) |
| October 2026 | [Krazati (adagrasib) primary completion](https://sec-api.dev/pdufa/adagrasib) | BMY | Advanced Cancer; Metastatic Cancer; Malignant Neoplasm of Lung | delayed | "NCT05853575 (Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10-30 (ESTIMATED); Lead Sponsor Mirati Therapeutics Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05853575)) |
| October 30, 2026 | [Bivamelagon topline data readout](https://sec-api.dev/pdufa/bivamelagon) | RYTM | Hypothalamic Obesity | completed | "NCT06046443 (A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-02-09 (ACTUAL); Lead Sponsor Rhythm Pharmaceuticals, Inc.; Results First Posted 2026-10-30." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06046443?tab=results)) |
| October 30, 2026 | [Apazunersen primary completion](https://sec-api.dev/pdufa/apazunersen) | RARE | Angelman Syndrome | withdrawn | "NCT06415344 (Long-term Extension of GTX-102 in Angelman Syndrome): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2026-10-30 (ACTUAL); Lead Sponsor Ultragenyx Pharmaceutical Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06415344)) |
| October 30, 2026 | [Apazunersen primary completion](https://sec-api.dev/pdufa/apazunersen) | RARE | Angelman Syndrome | withdrawn | "NCT07157254 (A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-10-30 (ACTUAL); Lead Sponsor Ultragenyx Pharmaceutical Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07157254)) |
| October 31, 2026 | [RECURSION PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/rxrx/catalysts) | RXRX |  | completed | "Recursion Reports Third Quarter 2026 Financial Results and Extends Cash Runway; Highlights Positive Clinical Data in REC-4881 and REC-1245, Sanofi Development Candidate Option and Appointment of Fred Hassan as Chair" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1601830/000160183026000144/exhibit991-q0326.htm)) |
| October 2026 | [Palazestrant primary completion](https://sec-api.dev/pdufa/palazestrant) | OLMA | Breast Cancer; Advanced Breast Cancer; Metastatic Breast Cancer | delayed | "NCT06016738 (OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-31 (ESTIMATED); Lead Sponsor Olema Oncology, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06016738)) |
| October 2026 | [Anvumetostat primary completion](https://sec-api.dev/pdufa/anvumetostat) | AMGN | MTAP-deleted NSCLC | delayed | "NCT06593522 (A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10-31 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06593522)) |
| October 2026 | [Truqap (capivasertib) primary completion](https://sec-api.dev/pdufa/capivasertib) | AZN | Breast Cancer | delayed | "NCT06635447 (Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-31 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06635447)) |
| October 2026 | [SPY002-072 primary completion](https://sec-api.dev/pdufa/spy002-072) | SYRE | Rheumatoid Arthritis; Psoriatic Arthritis; Axial Spondyloarthritis | delayed | "NCT07148414 (A Study of SPY072 in Rheumatic Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10-31 (ESTIMATED); Lead Sponsor Spyre Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07148414)) |
| October 2026 | [BRIUMVI® (ublituximab) primary completion](https://sec-api.dev/pdufa/ublituximab) | TGTX | Relapsing Multiple Sclerosis | delayed | "NCT07211633 (A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-31 (ESTIMATED); Lead Sponsor TG Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07211633)) |

Other months: https://sec-api.dev/fda-calendar/2026-09 , https://sec-api.dev/fda-calendar/2026-11. Calendar: https://sec-api.dev/fda-calendar

## Feeds and downloads

- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PDUFA dates October 2026: FDA calendar and catalysts." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/fda-calendar/2026-10

```bibtex
@misc{secapidev_fda_calendar_2026_10_20261116,
  title        = {PDUFA dates October 2026: FDA calendar and catalysts},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/fda-calendar/2026-10}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_fda_calendar_2026_10_20261116","title":"PDUFA dates October 2026: FDA calendar and catalysts","publisher":"sec-api.dev","URL":"https://sec-api.dev/fda-calendar/2026-10","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
